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ABSTRACT 
 
 
 
 
Academic research described in the late 1980’s the causal association between human 
papillomavirus (HPV) and cervical cancer, later expanded to significant fractions of all 
other genital tract cancers in both genders as well as a proportion of the cancers of the 
oral cavity and oropharynx. Prophylactic phase III HPV vaccine trials have shown 
complete type specific vaccine efficacy against two HPV types, namely HPV 16 and 18, 
that together account for over 70% of cervical cancer worldwide. HPV vaccines have 
proven in trials to have an excellent safety record. Most developed populations have 
introduced HPV vaccines as part of their routine vaccination schemes and introduction 
into developing countries is being actively planned. In 2012, over 100 million vaccine 
doses have been delivered and records of continuous efficacy and safety are 
encouraging.  Comprehensive strategies of HPV vaccination and HPV based screening 
tests could theoretically eliminate cervical cancer in defined populations.  
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1 Establishment of the causality link between 
HPV infections and cancer.  
 
1.1 Etiology 
 
The etiology of cervical cancer has been significantly linked to persistent infection 
with up to 15 strains of Human Papillomavirus (HPV). The association is consistent 
worldwide and causality has been generally accepted based on molecular 
epidemiological studies, including prevalence surveys, case control studies, cohort 
studies using cervical intraepithelial neoplasia (CIN) of grade 2/3 as surrogate 
endpoints, and screening studies. More recently, HPV vaccination trials have 
consistently concluded that vaccination against HPV types 16 and 18 could virtually 
eliminate the occurrence of HPV 16/18 related CIN 2/3 if given to individuals not 
carrying the infection at the time of vaccination, thus providing the ultimate proof of 
causality in human populations. 
 
The International Agency for Research on Cancer (IARC) Monograph Working 
Group(International Agency for Research on Cancer (IARC). 2007) concluded that 
there was sufficient evidence in humans for the carcinogenicity of HPV types 16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 in the cervix. HPV types 26, 66, 68 73, and 82 
were found to be associated with cervical cancer in some case-control studies, but the 
prevalence was very low in case series. For some rare types (HPV types 26, 53, 68, 73, 
and 82), the odds ratios (OR) observed are of similar magnitude to that of HPV 66 but, 
given the low prevalence observed in cases,  these types were temporarily classified as 
“probably” carcinogenic or, for HPV 66, as  “limited evidence”(Bouvard and Baan et al. 
2009). The consensus to date is that HPV is the central and necessary cause of cervical 
cancer and that at least fifteen HPV types are capable of inducing an invasive cancer.  
 
1.2 HPV DNA type distribution in cervical cancer and rationale for 
HPV 16 and 18 vaccines  
 
The distribution of HPV types in cervical cancer has been published in a pooled 
analysis of about 3000 cases from the IARC program (Munoz and Bosch et al. 2004) 
and in a meta-analysis of about 14,000 cases(Smith and Lindsay et al. 2007) The eight 
most common HPV types detected in both series, in descending order of frequency, 
were HPV types 16, 18, 45, 31, 33, 52, 58, and 35, and these are responsible for about 
90% of all cervical cancers worldwide. Two of the types - HPVs 16 and 18 -  are 
consistently found associated with at least 70% of the cases on several worldwide 
estimates(Bosch and Manos et al. 1995; de Sanjose and Quint et al. 2010; Munoz and 
Bosch et al. 2004) and these were identified as the two types included in the first 
generation of Virus like particle (VLP) HPV vaccines. The results have been recently 
confirmed in two landmark studies, one in the US population(Wheeler and Hunt et al. 
2009) and a large international survey, including specimens from close to 40 countries 
and slightly over 10,000 cervical cancers cases (de Sanjose and Quint et al. 2010) 
 
These two studies are critical because they used unified criteria for the field work, 
centralized laboratory protocols both for pathology and for HPV testing and typing and 
unified statistical treatment of the data, particularly on the causality attribution to any 
given HPV type when multiple infections were detected in a specimen. These two 
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studies largely overcome the limitations inherent to metanalyses and other forms of 
literature summaries. The HPV type distributions in cancer are geographically 
consistent in identifying HPV 16 and 18 followed by 45, 31 and 33 as the leading HPV 
types with moderate variability in the third and subsequent types (for example in the 
cases from Asia - particularly from Japan - where HPV types 58, 33 and 52 were 
relatively common). These distributions are sensitive to the technologies employed for 
HPV testing and typing as well as to the methods used to attribute causality when there 
are multiple HPV types in a given specimen. Of interest is the finding that cervical 
adenocarcinoma is a subtype of cervical cancer related almost solely to three HPV types 
(16, 18 and 45), with a 10-fold gap in prevalence between the third most common type 
and any other type (de Sanjose and Quint et al. 2010).  
 
1.3 The role of HPV in genital cancers other than cervical  
 
The available clinical and epidemiological studies indicate that cancers of the vagina 
and of the anus resemble cancer of the cervix with respect to the role of HPV. In both 
cases, HPV DNA is detected in the majority of tumors and particularly of their 
precursor lesions. In recent reviews, between 64% and 91% of vaginal cancer cases and 
82% and 100% of vaginal intraepithelial neoplasia of grade 3 (VAIN 3) lesions are 
HPV DNA-positive. In anal cancers in both genders, HPV DNA is detected in 88–94%. 
An estimated 40-50% of cancers of the vulva have also been associated with HPV as 
have some 40% of the penile carcinomas. The evidence available for some of these sites 
is not as comprehensive as for cervical cancer, although causality has been generally 
recognized (Forman D. 2012; International Agency for Research on Cancer (IARC). 
2007)  
 
In all HPV positive anogenital cancers, HPV 16 is the most common HPV type 
detected, followed by HPV types 18, 31, and 33. The combined contribution of HPV 16 
and 18 has been estimated in a range of 88-93 %, significantly higher that the relative 
contribution to cervical cancer. (de Vuyst and Clifford et al. 2009; Miralles-Guri and 
Bruni et al. 2009) 
   
1.4 The role of HPV in head and neck cancers 
 
HPV DNA can be consistently identified in a significant fraction of cancers of the 
oropharynx (i.e. in the 40 to 50% range) and in smaller proportions of the specimens of 
the remaining cancer of the oral cavity and the larynx (5 to 15%)(Gillison. 2012; 
Gillison and Koch et al. 2000)  
 
Cancers of the head and neck and particularly of the oropharynx are becoming of 
increasing interest since time trends suggests that incidence is on the rise; it strikes 
young individuals of both genders, is unrelated to alcohol or tobacco consumption and 
linked to patterns of sexual behaviour involving multiple partners and oral sex.(D'Souza 
and Fakhry et al. 2007; Heck and Berthiller et al. 2010; Rintala and Grenman et al. 
2006). For these cancers no screening opportunities have been previously identified. In 
estimates and projections of the cancer incidence in the US, it has been estimated that 
numerically these cancers are likely to become more frequent than cervical cancer 
(Chaturvedi and Engels et al. 2011) Similar trends have been observed in the Nordic 
countries (Nasman and Attner et al. 2009). However, the natural history of oral HPV 
infections and the additional risk factors of neoplastic transformation as well as the 
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characterization of the pre-neoplastic lesions that could be amenable to screening are 
largely unknown.  
 
Of interest is the observation that HPV related head and neck cancers are of 
increased sensitivity to treatments with chemotherapy and radiotherapy as compared to 
the HPV unrelated cases, usually linked to alcohol and tobacco consumption. HPV 
testing is increasingly adopted as part of the routine diagnostic work up of these cancers 
and is a useful guide to clinical management (Ragin and Taioli. 2007).  
 
2 Phase III vaccination trials: synthesis of the 
critical results 
 
There are currently two HPV vaccines identified as Gardasil® (Merck & Co., Inc., 
Whitehouse Station, NJ, USA) and Cervarix® (GlaxoSmithKline Biologicals, 
Rixensart, Belgium). Gardasil targets two oncogenic HPV types (16 and 18) and two 
non oncogenic HPV types (6 and 11) responsible for genital warts and respiratory 
papillomatosis. Cervarix targets two oncogenic HPV types (HPV 16 and 18) and is 
formulated with a novel adjuvant ASO4 included to boost the immune response. The 
essential results of the Phase III clinical trials have been already provided and these two 
vaccines are currently licensed in over 120 countries. Most developed countries have 
introduced HPV vaccines into routine vaccination programs with specific 
recommendations and more than one hundred million doses have already been 
distributed in 2011. 
  
Phase III results for both vaccines are available for women in the 15-26 age range 
(see table 2.1). Trials have examined vaccine efficacy (VE) in several cohorts of HPV 
unexposed and exposed women and in several age ranges. For simplicity, results in 
table 2.1 are presented in qualitative format and reflect VE in the most appropriate study 
cohort. In addition, several ancillary protocols have been completed or are under way 
including bridging studies in the 9-15 years of age for both girls and boys and in the 26-
45 years of age women. More limited information is also available of the VE in adult 
men and in special populations (immunosuppressed transplant patients, HIV infected 
populations, infants and other).  
 
[Table 2.1](Bosch and de Sanjosé et al. 2008; Schiller and Castellsague et al. 2008)  
 
These two vaccines have shown to date a very high efficacy against the predefined 
endpoint lesions (HPV 16 or 18 related CIN 2 or superior [CIN2+]), adequate safety and 
tolerability profiles, high immunogenicity, duration of protection so far of 7-8 years, 
and strong indications of ability to induce immune memory. Interestingly, some degree 
of cross protection against CIN 2+ related to other HPV types (HPV 31 for both 
vaccines and HPV 33 and 45 for Cervarix) has been documented. Therefore, the global 
estimates of the protection against cervical cancer of the currently available vaccines in 
properly vaccinated populations range from strictly 70% of the cervical cancer cases 
attributed to HPV 16 and 18 to a range of 75-80% adding non-vaccine HPV type cross-
protection. The latter however still requires some additional evaluation in terms of 
quantification of the vaccine efficacy estimates and on the potential duration of the 
protective effect of the types not included in the vaccine. None of the vaccines has 
shown therapeutic activity. Finally, it is important to note that these estimates show 
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little geographically variation, thus these vaccines should be considered of global 
validity.  
 
The limitations of current vaccines are known and include the lack of therapeutic 
effect, the limited impact of the cross protection effect and, as a consequence of the two, 
the requirement to continue some form of screening programs among vaccinated 
women. Finally, the cost of the production technology is high translating into the high 
cost of the vaccine at least in the early years after introduction in developed countries( 
Global Advisory Committee on Vaccine Safety 2009; Centers for disease control and 
prevention. 2009; European center for disease prevention and control (ECDC). 2008; 
Markowitz and Dunne et al. 2007; Schiller and Castellsague et al. 2008). 
 
In addition to the pivotal Phase III trials, additional research has generated critical 
information to guide the use of the HPV vaccines. Amongst the most relevant results, 
trials that have examined vaccine efficacy among women up to the age of 45 have 
shown that even though the antibody titers generated by vaccination are lower, 
protection against persistent infection and CIN 2+ lesions is high(Castellsague and 
Munoz et al. 2011). This observation prompts the suggestion of expanding the use of 
HPV vaccines beyond the currently recommended age groups. 
   
Although protection against other cancer sites was not the primary objective of the 
phase III trials, vaccinated women showed a remarkable reduction of the incidence of 
pre neoplastic lesions of the vulva (VIN 2/3) the vagina (VAIN 2/3) and in some trials 
of the preneoplatic lesions of the anal canal (AIN 2/3). Trials of the Gardasil vaccine 
have shown very high efficacy in the protection against genital warts in both males and 
females.(Schiller. 2012; Schiller and Castellsague et al. 2008)  
 
The vaccine efficacy observed in preventing genital warts in vaccinated men and the 
herd immunity observed among male populations coexisting with a highly vaccinated 
female population in Australia, allows the speculation that vaccination will also protect 
vaccinated males against the HPV-related fraction of penile carcinomas. It is unlikely 
that a specific trial would ever evaluate specifically the preventive potential of HPV 
vaccines against such a rare disease. However the observation deserves long term 
monitoring of trends in penile cancer incidence in populations that introduce male 
vaccination or that achieve very high vaccination rates among women. 
 
There is little information on the preventive potential against the HPV related 
cancers of the oropharynx or on the reduction of respiratory papillomatosis of the 
newborn and infants following generalized introduction of the vaccine Gardasil that 
includes VLP’s of HPV 6 and 11 as antigens.  
 
 
3 HPV vaccine introduction and early population- 
based results 
 
HPV vaccines were first used in 2006 and gained rapid support among international 
and national licensing offices and advisory boards. General recommendations gave 
priority (and in many instances allocated state supported vaccination costs) to young 
girls / adolescents prior to the average ages at onset of sexual activity. Catch-up 
vaccination of sexually active women is more variable across countries. Licensing has 
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been generally granted to ages 45 based on a limited number of trials showing safety, 
immunogenicity and efficacy against persistent HPV infection and CIN 2+ lesions.   
 
In countries with centralized programs and state supported vaccine costs, coverage 
of the target populations (adolescents and young girls) is very high and in a few 
settings, early evaluations of the clinical impact has already been shown. For example, 
in Australia an enlarged vaccination program offered for two years free vaccination to 
women up to the age of 26. The program was well coordinated amongst all stakeholders 
and coverage reached a significant 65-70% of the target population, girls 12-14, and 
some 50% coverage of the catch-up older population, women 15 to 26. In the program 
Gardasil was the only vaccine used. Early results were provided in an ecological type of 
study reporting on the relative contribution of genital warts to the series of clinical cases 
attended in a STD clinic in Melbourne (the average number of annual patients at the 
clinic was reported as close to 53,000 per year of which some 5000 attended because of 
genital warts). In this non controlled clinical observation, three years after vaccine 
introduction a significant reduction in the diagnosis of genital warts has been recorded 
and some indication of herd immunity is being documented. The latter is observed by a 
significant reduction in the number of episodes of genital warts amongst heterosexual 
males (largely non-vaccinated) in the same clinics where the reduction amongst females 
was documented. In the same analyses, genital warts in male homosexuals during the 
interval remained constant as was the level of all other STDs(Fairley and Hocking et al. 
2009). The analyses strongly suggest that the reduction in incidence of genital warts in 
males was a consequence of the high vaccination coverage of the female population in 
the same age range. A significant reduction of the cases of  CIN 1+ and CIN 2+ in these 
populations has been also recorded within the first four years of the vaccination 
program (Brotherton and Fridman et al. 2011).  
 
Very high coverage rates with Cervarix have also been achieved in the United 
Kingdom among the target populations aged 12-13 and the catch-up population of up to 
18 years of age. A significant advantage in coverage has been generally observed in 
areas where vaccination is offered in the context of school based programs. Similar 
observations have been reported within countries (i.e., the different autonomous regions 
in Spain) by comparing subpopulations served by school based programs with 
populations served by health centre based programs. Even with an equivalently 
centralized subsidy of the vaccine costs (the cost of the vaccination program has to be 
regionally supported), compliance is far better if controlled school based programs are 
implemented. 
 
A number of other examples have been reported from developing areas of the world 
where HPV vaccination has been introduced as part of controlled demonstration 
programs. One of such programs was lead by the Program for Appropriate Technology 
in Health (PATH) and explored strategies of vaccine introduction in four areas in Peru, 
Vietnam, India and Uganda. These projects have concluded amongst others that vaccine 
acceptance by the population is satisfactory, that a strategy of using school-based  
vaccination programs in urban areas is highly appropriate but combined programs of 
school and outreach visits is necessary in areas were the population is dispersed and 
school attendance is likely to be insufficient. Moreover, strategies based on campaigns 
in Uganda (Child Plus Days) unveiled the complexity of targeting girls based on age 
rather than on school grade. The former, particularly if age is restricted to single 
cohorts, generated a significant time loss and reduced coverage in trying to verify age.   
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In other populations of the developing world such as Bhutan or Panama where HPV 
vaccine was offered free of charge, vaccination coverage has been very satisfactory 
(Markowitz. 2012).   
 
 
4 Issues in vaccine use and introduction  
 
 
Early indications following Phase III trials were strongly driven by the priority of 
preventing cervical cancer. At this stage however, advances in the understanding of the 
spectrum of cancers related to HPV, the results of additional vaccination trials and the 
evolution of vaccine costs, strongly indicate that some the original preventive 
indications are unnecessarily self-limited. 
 
4.1 Single gender vaccination. 
 
HPV was first recognized as a cause of cervical neoplasia and all subsequent 
preventive efforts were oriented towards cervical cancer, the second most frequent 
cancer in women worldwide. However, research has identified the same HPV types, 
notably HPV 16, as the cause of a fraction of almost all genital tract cancers in men and 
women and more recently, of a significant fraction of cancers of the oral cavity and 
oropharynx. Furthermore, HPV vaccine trials in males have shown the potential of HPV 
vaccines to prevent genital warts (if Gardasil is used) and anal preinvasive lesions (AIN 
2/3).  
 
Previous experiences with other vaccines (i.e. rubella) showed that in certain 
cultural environments, female only vaccination prompted rumors and negative attitudes 
towards vaccination on the grounds of unjustified side effects or more extravagant 
proposals such as the existence of international plots to sterilize young women or other. 
As a result interruption or irregular coverage of all vaccines occurred and subsequent 
outbreaks of previously controlled infections such as polio virus occurred and spread to 
areas where the disease was already considered under control. Gender neutral 
vaccination and incorporation of the HPV vaccines into the expanded program of 
immunization (EPI) would bypass the problem and facilitate coverage.(Kane. 2012)  
 
Major arguments in favor of male vaccination are: i) the expected impact on herd 
immunity in populations where vaccination coverage among women is low (somehow 
arbitrarily defined as below 70%); ii) the impact of reducing genital warts in men, 
especially men who have sex with men (MSM), if Gardasil is used; iii) the impact on 
HPV-related cancers in males; and iv) avoidance of concerns in the population on the 
importance and motivation for HPV vaccination, potentially triggered by the promotion 
of single-gender vaccination. 
 
Some of the deterrents of the male vaccination proposal at this stage are: i) the late 
acquisition of the evidence of the burden of HPV related conditions in men as compared 
to the early focus on cervical cancer; ii) the limited evidence on the impact of HPV 
vaccines in men; and iii) the high price of the vaccines leading to concerns that male 
immunization is not cost-effective.  
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In this rapidly evolving field, vaccination trials among males have been 
satisfactorily conducted and licensing by regulatory agencies has already occurred in the 
US and other countries. However formal introduction into routine vaccination public 
programs has not yet been proposed. Some male populations at high risk of HPV 
infections and HPV related cancers (i.e., MSM) are potential target groups for first 
introduction of male HPV vaccination. (MMWR 2011; Palefsky and Giuliano et al. 
2011)  
 
4. 2 Target age groups for vaccination: 
 
The introduction of HPV vaccines into the routine immunization programs of peri-
adolescent girls in most developed countries is a major first step of preventive 
oncology.(Global Advisory Committee on Vaccine Safety. 2009) However the target 
ages for vaccination offers a canopy of national alternatives with limited scientific 
rationale. While all regulatory offices recognize the priority to vaccinate girls before 
sexual behaviour starts (in the range of 9 to 14 years of age), in Europe alone, the upper 
limit for vaccine recommendations range from single cohorts below the age of 14 in 
Spain and Norway to age 18 in the UK or Belgium, to age 23 in France and to age 26 in 
some regions in Italy and in Greece. More interestingly, the vaccination program in 
Australia, with an estimated national vaccination coverage of 50% in women up to the 
age of 26 with Gardasil achieved an almost disappearance of genital warts and a 
significant reduction of CIN 2+ lesions in the 4 year interval following the introduction 
of the vaccination program.  
 
Vaccination trials in women up to the age of 45 (Castellsague and Munoz et al. 
2011) have also shown that vaccine efficacy is high among women that are HPV DNA 
negative at study entry. It is known that HPV exposure can occur at any age group as 
long as the person is sexually active. Therefore vaccination can offer some degree of 
prophylactic benefit at any age group and the major deterrent to a generalized 
vaccination program with a difficult to determine upper age limit is vaccine cost. The 
discussion becomes particularly relevant when considering the reduction of the 
frequency of screening events required for vaccinated women and additional cost 
benefit analyses will have to be conducted accordingly.   
 
4.3 Predicted impact of vaccinating sexually adult women  
 
Phase III HPV vaccination trials have provided efficacy estimates in different 
cohorts, mimicking potential users in the population at large. The preventive value of 
HPV vaccines is better expressed in women that are naïve to the relevant HPV types at 
study entry and VE decayed rapidly when vaccinated cohorts were evaluated 
irrespective of the HPV status at study entry and with case counting starting on the day 
after the first dose is delivered (usually described as Intention To Treat [ITT] or Total 
Vaccinated Cohort [TVC] type of analyses). Based upon these observations in the early 
reports of the trials (interim analyses and analyses within the first 2/3 years of follow 
up), VE and vaccination of adult sexually active women was considered of little 
interest. However, with the observation of larger number of individuals for longer 
periods of follow up, VE estimates for the ITT/TVC cohorts significantly increased in 
both vaccines trials(Garland and Hernandez-Avila et al. 2007; Herrero R and Wacholder 
S et al. 2011).  This is explained because the CIN 2+ cases that are attributable to 
prevalent HPV infections or low grade lesions at study entry tend to occur in the first 
years of follow up and equally so in both the vaccinated and the controls groups. 
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However as time elapses, cases related to de novo HPV infections are observed and VE 
estimates increase significantly. Therefore, the potential for prevention of programs that 
target the general population at large irrespective of their HPV status at vaccination still 
needs to be assessed. Cost benefit analyses and related screening protocols will also 
have to pay attention to this observation.  
 
4.4 Cost of the vaccines 
 
The price of the vaccines when first introduced was significantly higher that any 
other widely used infant vaccines and similar to the initial prices of hepatitis B vaccines. 
Cost benefit analyses based on prices above 100E per dose in the private markets and 
similar in the public markets strongly limited the rapid introduction of the vaccine into 
developing countries and severely reduced vaccine indications in developed countries 
by restricting the target populations to one single age cohort in several of them. As 
expected, major efforts have been invested in lowering the price of vaccines including 
massive negotiations for procurement, tiered prices for emerging economies and very 
low prices for GAVI eligible countries. Other opportunities for price reduction in the 
future will probably come from ongoing studies evaluating alternative options such as 
two-dose regimes or different forms of packaging and delivering systems.  
  
With rapidly decreasing prices, the economic limitations that modulated the age 
ranges covered by the public system in developed countries may change and move 
towards wider vaccination indications such as the one adopted by the Australian 
Government. These considerations are likely to be particularly important in emerging 
economies and other regions in the world (i.e. eastern European countries, Turkey, 
Mexico etc) that are now at the planning phases of their national policies for cervical 
cancer prevention. (Andrus and Sherris et al. 2008) 
  
4.5 Alternative uses of HPV vaccines 
 
Ongoing trials and demonstration programs are now evaluating two-dose 
vaccination regimes instead of three using either of the available vaccines. Initial results 
in the Costa Rica trial (Herrero R and Wacholder S et al. 2011) looked at women who 
received one or two doses of Cervarix instead of a standard 3 dose regimen. In this trial, 
even one dose showed high antibody titers, not inferior to the titers in people receiving 
the conventional three dose schedule. Assessment of the efficacy and duration of 
protection with one or two doses requires further validation in formal comparative trials 
that are currently underway in India, Canada and elsewhere. 
 
Alternative schedules using longer intervals between the doses are other alternatives 
that are being tested in Mexico, Vietnam and in Quebec, Canada using schedules at 0, 6 
and 60 months.(Kreimer and Rodriguez et al. 2011; Neuzil and Canh et al. 2011) The 
protocol should be able to assess the efficacy of two doses as well as the convenience 
and impact of a booster dose 5 years after initiation of the vaccination scheme. Short 
term results from the program in Mexico suggest that two doses at 0 and 6 months 
induce higher antibody titers than the conventional 0 and 1 or 2 months. No efficacy 
results are so far available from these studies. (Lazcano, E et al. personal 
communication) 
 
One of the programs with Cervarix is examining the validity of administering the 
vaccine to infants aged 4 with a view to incorporate them into the EPI schedules. 
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Further studies in 0 to 1 year olds and co-administration formulations with the other EPI 
vaccines would represent a major advantage in terms of achieving high coverage and 
vaccination of males as well as females. However to date no major programs are under 
way to examine these options. 
 
 
5 Prospects for second generation vaccines and 
impact on preventive strategies 
 
Research is actively ongoing on the preparation of so-called second generation 
vaccines that would overcome some of the limitations of current vaccines.  
The first objective of the second generation HPV vaccines will be to address the 
spectrum of HPV types by increasing the number of antigens. Trials of a nonavalent 
HPV (including HPV 6, 11, 16, 18, 45, 31, 33, 52, 58) vaccine targeting protection 
against the HPV types that cause 90% of cervical cancer as well as genital warts are 
currently in advanced Phase III trials and results are awaited in 2012. 
 
A similar end result could be achieved (i.e VE >90%) by Cervarix if the reported 
impact on CIN 3+ lesions irrespective of HPV type (93.2%VE) is shown to persist over 
time. 
 
Other alternatives to increase the valency of HPV vaccines is exploring L2 based 
constructs and cheaper high throughput production systems. These vaccines are 
currently in the early days and entering Phase I trials(Jagu and Karanam et al. 2009).  
Figure 1 (adapted from(Bosch. 2009)) shows a speculative diagram on plausible 
protocols for cervical cancer prevention with broad spectrum vaccines in developing 
and developed countries. Details of several of the steps of the proposal will require 
additional clinical research for verification and recommendation.  
 
[Figure 1] adapted from(Bosch. 2009).  
 
According to the scheme, HPV vaccination of women could be proposed as broad as 
feasible in terms of age groups while retaining the emphasis on young pre-sexual 
initiation girls who would not need further screening. Needless to say, some safety 
evaluations of the proposal would be necessary in focused clinical trials early in the 
process. 
 
Vaccinated sexually active young women (i.e. before the ages of 25/30 but years 
after sexual initiation) could be offered a single event HPV screening when reaching the 
age of 25 or 30. The screen would identify the group of women that were already HPV-
positive before vaccination and remained persistently infected who would then be 
followed.  
 
Women at ages 30 to 45 + could be offered broad spectrum HPV vaccines at the 
time that a single HPV screen is offered.  In the screening event, women found HPV 
negative (80 to 90% of the target population) will complete the HPV BS vaccination 
program with no further screening requirements over their lifetime. For women that 
turned out to be HPV positive, diagnostic and follow-up procedures (colposcopy / 
biopsy / surgery) could be activated in parallel with completion of the vaccination 
 11
DEVELOPED COUNTRIES DEVELOPING COUNTRIES
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(≈ 90%)
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(≈ 10%)
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(≈ 20%)
HPV negative
(≈ 80%)
VIA w/o 
Cryotherapy‡
CERVICAL CANCER PREVENTION STRATEGIES USING BROAD SPECTRUM HPV VACCINES
BS= Broad spectrum; HPV=Human Papillomavirus; VIA= Visual inspection with acet ic acid 
‡ = Details of such protocols would require additional clinical research; = Vaccination event
Figure 1
Adapted from (Bosch 2009) 
scheme. Following treatment of the CIN 2+ cases identified, HPV screening could be 
further used once/twice in their lifetime as a proof of cure and a safety net.  
Whatever the final format of the protocols, broad spectrum vaccines have the potential 
to i) alleviate the health services demand of the repeated screening protocols currently 
in use ii) influence the cost benefit analyses in favor of generalized vaccination and iii) 
trigger a significant reduction in cervical cancer mortality over a medium term, well 
before the long term benefits of the generalized adolescent HPV vaccination are clearly 
visible. 
 
Developing countries would follow a similar protocol, while using an adapted HPV 
testing system (i.e., the Care HPV testTM, Qiagen Gaithersburg, Inc., MD, USA) and 
triage protocol for women testing HPV positive(Blumenthal and Lauterbach et al. 2005; 
Sankaranarayanan and Gaffikin et al. 2005). The HPV DNA test adapted for use in 
developing populations achieved significant features of simplicity (average lab 
technicians can be trained to use them) technical demands (do not require electricity or 
running water) and output (sampling and testing can be achieved in significant numbers 
over one shift period) thus allowing for strategies of testing and treating within the 
duration of the preventive event.   
 
In brief, the use of BS HPV vaccines should significantly reduce or terminate the 
requirement for continuous screening among vaccinated adolescents and dramatically 
simplify the strategy for cervical cancer prevention in sexually active adult women in 
both developed and developing countries. They will help closing the equity gap in 
cervical cancer prevention between developed and developing populations. 
 
 
6.  Screening implications of generalized HPV 
vaccination 
 
6.1 developed populations  
 
It has been repeatedly shown that under the best technical conditions, using the Pap 
smear as the primary screening test, paired with colposcopy and biopsy as the 
diagnostic tools, the achievable reduction in cervical cancer incidence and mortality is 
in the range of 50 to 80 % in countries with centrally organized efforts. In countries 
with opportunistic screening the impact in cervical cancer reductions is generally  
lower. Likewise, it could be speculated that the reduction in cervical cancer incidence 
would be in the 80-85 +% range using HPV tests as the primary screening option with 
some additional triage test (cytology, HPV typing, p16+Ki 67 stains) to guide 
management. Even in well screened populations in Sweden or within a private 
insurance plan in California, some cervical cancer cases occur and these are attributed to 
either lack of participation to the screening program (56 - 64 % of the cases), false 
negative results of the Pap smear ( 32 - 24  % of the cases) or lack of follow up of 
women found at high risk in the cytology results ( 13 -11  % of the cases).(Andrae and 
Kemetli et al. 2008; Leyden and Manos et al. 2005) These seem to be nowadays the 
population limits of Pap smear based screening programs.    
 
Developed countries have now the opportunity to benefit from HPV related 
technologies by implementing  strategic combinations of population based HPV 
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vaccination with a second generation screening technology program for the prevention 
of cervical cancer. Vaccinated populations will experience a dramatic reduction in the 
incidence of CIN 2+ due to HPV 16 and 18 (over 60% of the CIN 2+ cases) and 
consequently the validity of the Pap smear as primary screening test will suffer.  
A reduction by half of the underlying prevalence of the conditions of interest (CIN2+) 
will imply a significant loss in predictive value.(Franco and Cuzick et al. 2006; Franco 
and Mahmud et al. 2009) Populations such as the Australian or the British that are 
currently vaccinating women that will soon enter the recommended screening age 
groups are appropriate scenarios to test at a large scale the validity of HPV based tests 
as primary screening tools and will serve as guidance for future planning in other 
countries. 
 
Additional public health and clinical research will help define the details of the most 
effective and cost-effective combinations of mass vaccination and second generation 
screening and triage protocols. However it can now be speculated that in defined 
developed populations with good preventive care services and adequate attention to 
immigrant populations, cervical cancer can be drastically reduced to achieve the level of 
disease elimination within a reasonable time frame. 
 
6.2 developing populations 
 
With few exceptions, developing populations have irregularly benefited from the 
conventional pap smear based screening strategy and numerous reviews have 
documented the reasons for the failure.  Many of these are structural and social, thus 
requiring significant improvement of the public health services to achieve the results 
described for developed populations. This being the case, cervical cancer remains the 
third leading cancer in women worldwide and the number one or second cancer in 
women in 82 % of the 127 developing nations. Moreover, because in these countries 
cervical cancer strikes at young ages and significantly so among young women (i.e.<45 
years of age) cervical cancer is a major component of the number of years of life lost to 
cancer.  
 
In recent years, low technology tests for secondary prevention of cervical cancer in 
developing countries have been proposed and evaluated, such as direct visual inspection 
of the cervix with or without acetic acid [visual inspection with acetic acid (VIA)]. The 
validity of the test is limited, requires careful training and supervision of the observers 
and has generated inconsistent results in different settings. These methods are usually 
included in “see and treat” or “screen and treat” programs in order to minimize attrition 
in the follow-up of screened women. However the number of false positives and over 
treatments is considerable and its use has not been generally endorsed(Cuzick and 
Arbyn et al. 2008).  
 
In contrast to the limited success of pap-smear based screening programs, 
developing countries have achieved outstanding results in vaccinating the infant and 
pediatric age groups. Vaccination in the Expanded Program of Immunization (EPI) is 
very high in virtually all developing populations, thanks to a great extent to 
international organizations and donors such as the World Health Organization (WHO), 
GAVI (formerly The Global Alliance for Vaccines and Immunisation), the United 
Nations Children's Fund (UNICEF), the Bill & Melinda Gates Foundation and others. 
Eradication of small pox was archived and elimination or significant control of polio, 
measles and other infectious diseases has been successful in most developing nations. 
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Therefore, vaccination against HPV seems a relevant option as well as a realistic one to 
address cervical cancer prevention. Like in developed countries, adult sexually active 
women, in extensive populations in developing countries could benefit from the already 
available novel form of HPV DNA screening test, technologically adapted to be used in 
low development level scenarios(Andrus and Sherris et al. 2008; Qiao and Sellors et al. 
2008; Sankaranarayanan and Bhatla et al. 2008; Sankaranarayanan and Nene et al. 
2009; (World health organization. 2009).  
 
 
7 Opportunities for research and progress  
 
Academic research has made tremendous advancements in providing the 
understanding of the causes of cervical cancer and generating the technology to prevent 
it both at the primary and secondary levels. Anticipated developments in the years to 
come can be summarized as follows: 
 
7.1 Etiology: completion of studies linking and quantifying the impact of HPV 
infections in the etiology of ano-genital cancer and cancer of the head and neck. 
7.2 Screening. Screening programs in the public system are likely to gradually adopt 
HPV tests as the primary screening tool. The related clinical protocols will require 
additional studies to define the management of HPV + women with normal cytology. 
HPV-DNA testing technologies adapted to developing countries (i.e. Care HPV test) 
will be gradually tested and introduced in developing countries. 
7.3 HPV vaccines. Research on novel HPV vaccines to be developed will continue both 
in the direction of increasing the valence of the vaccines and/or by including therapeutic 
components in the vaccine products. 
7.4 Adoption of HPV vaccines. Continued developments in vaccine development 
should evolve in parallel to (and learn from) the implementation experiences. Efforts to 
introduce HPV vaccines in all countries should be strongly encouraged and it would be 
unjustified to delay it on the grounds of the promise of better vaccines on the horizon.  
7.5 Integrated cervical cancer control. Logistical research and modeling studies will 
help define the most adequate strategies to address comprehensive cancer prevention 
strategies in extensive areas and populations where no preventive options are available 
nowadays. 
7.6 Disease awareness and medical education. These will aim at 1) increasing the low 
level of awareness on the impact of cervical cancer worldwide and particularly in 
developing countries ii) address issues of cervical cancer as a single gender disease and 
the stigma of being linked to a sexually transmitted infection (STI) and iii) counteract 
the negative publicity on vaccines and HPV vaccination in the media . 
7.3 Social consensus on cervical cancer prevention. Political efforts are now needed 
towards introducing the concepts of cervical cancer elimination and eradication and 
help reaching the stage at which the public health community at large embarks on the 
required worldwide effort.  
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Conclusion 
 
Technologies to dramatically reduce the impact of cervical and other HPV related 
cancers are now available. HPV vaccines and HPV based screening tests might 
represent the technical requirements to begin closing the equity gap in cervical cancer 
prevention between developed and developing countries.  
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